Signaling pathway components of immune checkpoint PD-1/PD-L1 in blood plasma of patients with ovarian cancer and benign ovarian tumors: clinical and morphological correlations
- Autores: Kushlinskii N.E.1, Gershtein E.S.1, Utkin D.O.2, Petrikova N.A.3, Kushlinskiy D.N.4, Shabanov M.A.1, Khulamkhanova M.M.1, Ashrafyan L.A.5, Stilidi I.S.1
-
Afiliações:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
- Ryazan Regional Clinical Oncology Dispensary
- A.F. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Center of Radiology
- Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
- Edição: Nº 6 (2020)
- Páginas: 80-88
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248882
- DOI: https://doi.org/10.18565/aig.2020.6-80-88
- ID: 248882
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Nikolay Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: kne3108@gmail.com
MD, Professor, Member of the Russian Academy of Sciences, Head of the Laboratory of Clinical Biochemistry
Elena Gershtein
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: esgershtein@gmail.com
PhD, Doctor Biol. Sci, Professor, Leading Researcher, Laboratory of Clinical Biochemistry
Dmitry Utkin
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Email: utkindo@yandex.ru
applicant
Natalya Petrikova
Ryazan Regional Clinical Oncology Dispensary
Email: petrikova.nat@yandex.ru
Pathologist, Department of Pathologic Anatomy with Pathomorphologic Laboratory
Dmitry Kushlinskiy
A.F. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Center of Radiology
Email: drkushlinskiy@gmail.com
senior researcher, Department of combined and surgical methods of treatment of gynecological diseases
Mikhail Shabanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: 0l52@mail.ru
MD, Professor, leading researcher, Department of morphologic and molecular genetic tumor diagnostics
Marina Khulamkhanova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: marina_2705@list.ru
oncologist
Lev Ashrafyan
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: Levaa@yahoo.com
MD, Professor, Member of the Russian Academy of Sciences, Director of the Institute of Oncogynecology and Mammology
Ivan Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: Stylidi@ronc.ru
MD, Professor, Member of the Russian Academy of Sciences, director
Bibliografia
- Zhu X., Lang J. The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: a systematic review. Gynecol. Oncol. 2016; 142(1): 184-9. https://dx.doi.org/10.1016/j.ygyno.2016.04.002.
- Mandai M., Hamanishi J., Abiko K., Matsumura N., Baba T., Konishi I. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int. J. Clin. Oncol. 2016; 21(3): 456-61. https://dx.doi. org/10.1007/s10147-016-0968-y.
- Inayama Y., Hamanishi J., Matsumura N., Murakami R., Abiko K., Yamaguchi K. et al. Antitumor effect of nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer. Oncologist. 2018; 23(11): 1382-4. https://dx.doi. org/10.1634/theoncologist.2018-0167.
- Yun S., Vincelette N.D., Green M.R., Wahner Hendrickson A.E., Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 2016; 5(7): 1481-91. https://dx.doi.org/10.1002/cam4.732.
- Massari F., Santoni M., Ciccarese C., Santini D., Alfieri S., Martignoni G. et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat. Rev. 2015; 41(2): 114-21. https://dx.doi.org/10.1016/j. ctrv.2014.12.013.
- Кушлинский Н.Е., Фридман М.В., Морозов А.А., Герштейн Е.С., Кадагидзе З.Г., Матвеев В.Б. Современные подходы к иммунотерапии рака почки. Онкоурология. 2018; 14(2): 54-67. https://dx.doi.org/10.17650/1726-9776-2018-14-2-54-67. [Kushlinskii N.E., Fridman M.V., Morozov A.A., Gershtein E.S., Kadagidze Z.G., Matveev V.B. Modern approaches to kidney cancer immunotherapy. Cancer Urology. 2018; 14(2): 54-67. (In Russian)].
- Zhu X., Xu J., Cai H., Lang, J. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model. J. Obstet. Gynaecol. Res. 2018; 44(2): 303-11. https://dx.doi.org/10.1111/jog.13521.
- Yuasa T., Masuda H., Yamamoto S., Numao N., Yonese J. Biomarkers to predict prognosis and response to checkpoint inhibitors. Int. J. Clin. Oncol. 2017; 22(4): 629-34. https://dx.doi.org/10.1007/s10147-017-1122-1.
- Zhang Y., Kang S., Shen J., He J., Jiang L., Wang W. et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore). 2015; 94(6): e515. https://dx.doi.org/10.1097/MD.0000000000000515.
- Sacher A.G., Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2016; 2(9): 1217-22. https://dx.doi.org/10.1001/jamaoncol.2016.0639.
- Kim K.S., Sekar R.R., Patil D., Dimarco M.A., Kissick H.T., Bilen M.A. et al. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Oncoimmunology. 2018; 7(4): e1413519. https://dx.doi.org/10.1080/2162402X.2017.1413519.
- Huang X., Zhang W., Zhang Z., Shi D., Wu F., Zhong B., Shao Z. Prognostic value of programmed cell death 1 ligand-1 (PD-L1) or PD-1 expression in patients with osteosarcoma: a meta-analysis. J. Cancer. 2018; 9(14): 2525-31. https:// dx.doi.org/10.7150/jca.25011.
- Drakes M.L., Mehrotra S., Aldulescu M., Potkul R.K., Liu Y., Grisoli A. et al. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. J. Ovarian Res. 2018; 11(1): 43. https://dx.doi.org/10.1186/s13048-018-0414-z.
- Darb-Esfahani S., Kunze C.A., Kulbe H., Sehouli J., Wienert S., Lindner J. et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016; 7(2): 1486-99. https://dx.doi. org/10.18632/oncotarget.6429.
- Strickland K.C., Howitt B.E., Shukla S.A., Rodig S., Ritterhouse L.L., Liu J. F. et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016; 7(12): 13587-98. https://dx.doi.org/10.18632/oncotarget.7277.
- Wieser V., Gaugg I., Fleischer M., Shivalingaiah G., Wenzel S., Sprung S. et al. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget. 2018; 9(25): 17501-11. https://dx.doi. org/10.18632/oncotarget.24770.
- Howitt B.E., Strickland K.C., Sholl L.M., Rodig S., Ritterhouse L.L., Chowdhury D. et al. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2): e1277308. https:// dx.doi.org/10.1080/2162402X.2016.1277308.
- Topalian S.L., Taube J.M., Anders R.A., Pardoll D.M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer. 2016; 16(5): 275-87. https://dx.doi.org/10.1038/ nrc.2016.36.
- Zhu X., Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017; 8(57): 97671-82. https://dx.doi.org/10.18632/ oncotarget.18311.
- Ding Y., Sun C., Li J., Hu L., Li M., Liu J. et al. The prognostic significance of soluble programmed death ligand 1 expression in cancers: a systematic review and meta-analysis. Scand. J. Immunol. 2017; 86(5): 361-7. https://dx.doi. org/10.1111/sji.12596.
- Wei W, Xu B., Wang Y., Wu C., Jiang J., Wu C. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. Medicine(Baltimore). 2018; 97(3): e9617. https://dx.doi. org/10.1097/MD.0000000000009617.
- Theodoraki M.N., Yerneni S.S., Hoffmann T.K., GoodingW.E., Whiteside T.L. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin. Cancer Res. 2018; 24(4): 896-905. https://dx.doi. org/10.1158/1078-0432.CCR-17-2664.
- Kim H.J., Park S., Kim K.J., Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother. Oncol. 2018; 129(1): 130-5. https://dx.doi. org/10.1016/j.radonc.2017.11.027.
- Guo X., Wang J., Jin J., Chen H., Zhen Z., Jiang W. et al. High serum level of soluble programmed death ligand 1 is associated with a poor prognosis in Hodgkin lymphoma. Transl. Oncol. 2018; 11(3): 779-85. https://dx.doi. org/10.1016/j.tranon.2018.03.012.
- Chatterjee J., Dai W., Aziz N.H.A., Teo P.Y., Wahba J., Phelps D.L. et al. Clinical use of programmed cell death-1 and its ligand expression as discriminatory and predictive markers in ovarian cancer. Clin. Cancer Res. 2017; 23(13): 3453-60. https://dx.doi.org/10.1158/1078-0432.CCR-16-2366.
- Кушлинский Н.Е., Герштейн Е.С., Морозов А.А., Горячева И.О., Филипенко М.Л., Алферов А.А., Бежанова С.Д., Базаев В.В., Казанцева И. А. Растворимый лиганд рецептора контрольной точки иммунитета (sPD-L1) в сыворотке крови при почечно-клеточном раке. Бюллетень экспериментальной биологии и медицины. 2018; 166(9): 325-9. [Kushlinskii N.E., Gershtein E.S., Morozov A.A., Goryatcheva I.O., Filipenko M.L., Alferov A.A., Bezhanova S.D., Bazaev V.V., Kazantseva I.A. Soluble ligand of immune checkpoint receptor (sPD-L1) in blood serum of renal-cell carcinoma patients: clinical and pathologic correlations. Bulletin of Experimental Biology and Medicine. 2018; 166(9); 325-9 (In Russian)].
- Герштейн Е.С., Уткин Д.О., Горячева И.О., Хуламханова М.М., Петрикова Н.А., Виноградов И.И., Алферов А.А., Стилиди И.С., Кушлинский Н.Е. Растворимые формы рецептора контрольной точки иммунитета PD-1 и его лиганда PD-L1 в плазме крови больных новообразованиями яичников Альманах клинической медицины. 2018; 46(7): 690-8. https://dx.doi.org/10.18786/2072-0505-2018-46-4-323-329.
- Zheng Z., Bu Z., Liu X., Zhang L., Li Z., Wu A. et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin. J. Cancer Res. 2014;26(1): 104-111. https://dx.doi.org/10.3978/j. issn.1000-9604.2014.02.08.
- Finkelmeier F., Canli O., Tal A., Pleli T., Trojan J., Schmidt M. et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur. J. Cancer. 2016; 59: 152-9. https://dx.doi.org/10.1016/j.ejca.2016.03.002.
- Zhang J., Gao J., Li Y., Nie J., Dai L., Hu W. et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac. Cancer. 20156(4): 534-8. https://dx.doi. org/10.1111/1759-7714.12247.